Symptoms of Depression and Anxiety, and Screening for Mental Disorders in Migrainous Patients

Kowacs, Fernando; Socal, Mariana P.; Ziomkowski, Sofia; Borges-Neto, V. F.; Toniolo, D.; Francesconi, C. R.M.; Chaves, Márcia Lorena Fagundes

doi:10.1046/j.1468-2982.2003.00461.x

Cited by 17 publications

(9 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The difference between psoriasis and controls was greatest when using the HADS questionnaire (n ¼ 3 studies) with a pooled OR of 8.00 (95% CI 1.42-45.17). Only one study used the MADRS questionnaire and its primary objective was to EA Dowlatshahi et al compare depressive symptoms in migraine patients with those in psoriasis patients and healthy controls (Kowacs et al, 2003). In this study, depressive symptoms were not significantly elevated in the psoriasis group compared with the controls (OR 2.13, 95% CI 0.76-3.27; Table 2).…”

Section: Odds Of Depressive Symptomsmentioning

confidence: 68%

The Prevalence and Odds of Depressive Symptoms and Clinical Depression in Psoriasis Patients: A Systematic Review and Meta-Analysis

Dowlatshahi

Wakkee

Arends

et al. 2014

Journal of Investigative Dermatology

333

278

View full text Add to dashboard Cite

The reported prevalence of depression in psoriasis varies substantially. This study aims to determine the prevalence and odds of depressive symptoms and clinical depression in psoriasis. A systematic literature search was conducted. Mean questionnaire values and proportions for depressive symptoms and clinical depression were pooled according to different assessment methods. In controlled studies, standardized mean differences (SMDs) and odds ratio (OR) compared depression in psoriasis patients with controls using the random-effect model. The majority of the 98 eligible studies were conducted in tertiary centers without a control group. The prevalence of depressive symptoms was 28% using questionnaires and the prevalence of clinical depression was 12% using International Classification of Diseases codes, 19% using Diagnostic and Statistical Manual of Mental Disorders IV, and 9% for antidepressant use. Psoriasis patients had significantly more depressive symptoms (SMD 1.16; 95% confidence interval (CI) 0.67-1.66), and population-based studies showed that they were at least one and a half times more likely to experience depression (OR 1.57; 95% CI 1.40-1.76) and used more antidepressants than did controls (OR 4.24, 95% CI 1.53-11.76). More than 10% of psoriasis patients suffer from clinical depression, and twice as many have depressive symptoms. The high prevalence of these symptoms is likely to be affected by the tertiary study populations and differential misclassification using questionnaires, where psoriasis-related symptoms may be detected as depressive symptoms.

show abstract

Section: Odds Of Depressive Symptomsmentioning

confidence: 68%

The Prevalence and Odds of Depressive Symptoms and Clinical Depression in Psoriasis Patients: A Systematic Review and Meta-Analysis

Dowlatshahi

Wakkee

Arends

et al. 2014

Journal of Investigative Dermatology

333

278

View full text Add to dashboard Cite

show abstract

“…Concerning headaches and psychological symptoms, there was no statistical difference between psychological symptoms and headache types. In a study carried out by Kowacs and et al (63), a significant association of general psychiatric symptoms with migraine was found. The present data for the migraine group and TTH group also indicated that somatisation in both groups was significantly higher than that in the headache‐free group.…”

Section: Discussionmentioning

confidence: 91%

Examination of anxiety, hostility and psychiatric disorders in patients with migraine and tension-type headache

Bag

Hacıhasanoğlu

Tüfekçi

2005

International Journal of Clinical Practice

View full text Add to dashboard Cite

The role of psychological factors related to headache has long been a focus of investigation. The aim of this study was to evaluate anxiety, depression, hostility and psychological symptoms in patients with migraine and tension-type headache (TTH) and to compare the results with healthy controls. Seventy-five subjects with migraine and 55 subjects with TTH (according to the criteria of the International Headache Society classification) and a control group including 73 healthy subjects were studied. The Buss-Durkee Hostility Inventory, Brief Symptom Inventory, State-trait Anxiety Inventory, Trait form were administered to the subjects. Compared with healthy controls, the patients with headache had significantly higher scores on measures of anxiety, depression and hostility and lower scores on psychological symptoms. The present results indicate the need to distinguish the unique dimensions of anxiety, depression and hostility that should be assessed in the population with headaches.

show abstract

“…In this study, patients were administered with BDI to address depressive features, which is a well-validated scale that has been used extensively in such populations before [10, 39]; this scale was not significantly affected by adding LCM. Anxiety is another one of the commonest complaints in patients undergoing antiepileptic therapy (see [3, 5]); we showed that STAI questionnaires, which explore anxiety trait and state and have been validated in several populations affected by chronic neurological illnesses [39–41], are not modified by LCM add-on. However, it should be noted that both depressive and anxiety features at t 0 were slightly elevated in our patients as compared to control populations from our lab historical data (not shown).…”

Section: Discussionmentioning

confidence: 99%

A Clinical-EEG Study of Sleepiness and Psychological Symptoms in Pharmacoresistant Epilepsy Patients Treated with Lacosamide

Giorgi

Pizzanelli

Pelliccia

et al. 2013

Epilepsy Research and Treatment

View full text Add to dashboard Cite

Our aim was to evaluate the EEG and clinical modifications induced by the new antiepileptic drug lacosamide (LCM) in patients with epilepsy. We evaluated 10 patients affected by focal pharmacoresistant epilepsy in which LCM (mean 250 mg/day) was added to the preexisting antiepileptic therapy, which was left unmodified. Morning waking EEG recording was performed before (t0) and at 6 months (t1) after starting LCM. At t0 and t1, patients were also administered questionnaires evaluating mood, anxiety, sleep, sleepiness, and fatigue (Beck Depression Inventory; State-Trait Anxiety Inventory Y1 and Y2; Pittsburgh Sleep Quality Index; Epworth Sleepiness Scale; Fatigue Severity Scale). We performed a quantitative analysis of EEG interictal abnormalities and background EEG power spectrum analysis. LCM as an add-on did not significantly affect anxiety, depression, sleepiness, sleep quality, and fatigue scales. Similarly, adding LCM to preexisting therapy did not modify significantly patient EEGs in terms of absolute power, relative power, mean frequency, and interictal abnormalities occurrence. In conclusion, in this small cohort of patients, we confirmed that LCM as an add-on does not affect subjective parameters which play a role, among others, in therapy tolerability, and our clinical impression was further supported by evaluation of EEG spectral analysis.

show abstract

Symptoms of Depression and Anxiety, and Screening for Mental Disorders in Migrainous Patients

Cited by 17 publications

References 58 publications

The Prevalence and Odds of Depressive Symptoms and Clinical Depression in Psoriasis Patients: A Systematic Review and Meta-Analysis

The Prevalence and Odds of Depressive Symptoms and Clinical Depression in Psoriasis Patients: A Systematic Review and Meta-Analysis

Examination of anxiety, hostility and psychiatric disorders in patients with migraine and tension-type headache

A Clinical-EEG Study of Sleepiness and Psychological Symptoms in Pharmacoresistant Epilepsy Patients Treated with Lacosamide

Contact Info

Product

Resources

About